Patents by Inventor Muthusamy Thangaraju

Muthusamy Thangaraju has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200289444
    Abstract: Compositions and methods for supporting health, especially renal health, comprising ketonic agents that recapitulate beneficial effects of ketosis by exogenously administered agents. The agents include BHB, analogs thereof, and GPR109A agonists. The agents may further include crystal precipitation inhibitors which synergistically improve treatment of certain renal conditions. The agents may be used in dietary supplements and therapeutic compositions for the treatment of cystic kidney diseases such as polycystic kidney disease, ciliopathies, and other conditions.
    Type: Application
    Filed: March 14, 2020
    Publication date: September 17, 2020
    Applicants: The Regents of the University of California, Augusta University Research Institute
    Inventors: Weimbs Thomas, Jacob Torres, Muthusamy Thangaraju
  • Publication number: 20140024663
    Abstract: The present invention includes inhibitors of the amino acid transporter ATB0,+ and methods of uses thereof for the treatment of estrogen receptor-positive breast cancer.
    Type: Application
    Filed: July 12, 2013
    Publication date: January 23, 2014
    Inventors: VADIVEL GANAPATHY, MUTHUSAMY THANGARAJU
  • Patent number: 8436039
    Abstract: The present invention includes inhibitors of the amino acid transporter ATB0,+ and methods of uses thereof.
    Type: Grant
    Filed: October 8, 2009
    Date of Patent: May 7, 2013
    Assignee: Georgia Health Sciences University Research Institute, Inc.
    Inventors: Vadivel Ganapathy, Muthusamy Thangaraju, Puttur Prasad
  • Patent number: 8309534
    Abstract: Pharmaceutical compositions containing an effective amount of a ligand for GPR109 to decrease intracellular cAMP levels of a subject in combination with an effective amount of a DNA methyl transferase inhibito to reduce or inhibit downregulation of GPR109 in the intestinal epithelial cells of the subject relative to a control are provided. It has been discovered that ligands for GPR109 can be used to treat one or more symptoms of cancer, inflammatory disorders, and diarrhea. Representative CPR109 ligands include, but are not limited to butyrate, ?-hydroxybutyrate, nicotinic acid, acifran, and octanoate. Suitable DNA methyl transferase inhibitors include 5-azacytidine, 5-aza-2?-deoxytidine, 1-?-D-arabinfarnosyl-5-azacytosine and dihydro-5-azacytidine. Typically, the compositions are formulated to achieve a GPR109 ligand serum blood level of about 1 to about 1000 ?M. The compositions are useful for the treatment of one or more symptoms of cancer.
    Type: Grant
    Filed: May 15, 2008
    Date of Patent: November 13, 2012
    Assignee: Medical College of Georgia Research Institute, Inc.
    Inventors: Vadivel Ganapathy, Puttur D. Prasad, Muthusamy Thangaraju, Gail Cresci
  • Publication number: 20100305184
    Abstract: The present invention includes inhibitors of the amino acid transporter ATB0,+ and methods of uses thereof.
    Type: Application
    Filed: October 8, 2009
    Publication date: December 2, 2010
    Inventors: Vadivel Ganapathy, Muthusamy Thangaraju, Puttur Prasad
  • Publication number: 20100137236
    Abstract: Pharmaceutical compositions containing an effective amount of a ligand for GPR109 to decrease intracellular cAMP levels of a subject in combination with an effective amount of a DNA methyl transferase inhibito to reduce or inhibit downregulation of GPR109 in the intestinal epithelial cells of the subject relative to a control are provided. It has been discovered that ligands for GPR109 can be used to treat one or more symptoms of cancer, inflammatory disorders, and diarrhea. Representative CPR 109 ligands include, but are not limited to butyrate, ?-hydroxybutyrate, nicotinic acid, acifran, and octanoate. Suitable DNA methyl transferase inhibitors include 5-azacytidine, 5-aza-2?-deoxytidine, 1-?-D-arabinf?mosyl-5-azacytosine and dihydro-5-azacytidine. Typically, the compositions are formulated to achieve a GPR 109 ligand serum blood level of about 1 to about 1000 ?M. The compositions are useful for the treatment of one or more symptoms of cancer.
    Type: Application
    Filed: May 15, 2008
    Publication date: June 3, 2010
    Inventors: Vadivel Ganapathy, Puttur D. Prasad, Muthusamy Thangaraju, Gail Cresci